Pompeu Fabra University is a university in Barcelona, Catalonia, Spain. Founded in 1990, it is named after the Catalan philologist Pompeu Fabra. Currently , the University offers 22 undergraduate degrees, 25 official masters, and 9 PhD programs, as well as around 100 UPF masters. It is currently the only Spanish university to figure in the Times Higher Education top 200 ranking at position 164. Wikipedia.
University Pompeu Fabra | Date: 2017-03-29
The present invention belongs to the field of virology and is related to agents with antiviral activity against enveloped viruses, particularly anti-HIV and anti-HCV activity, and methods for the prevention of viral infection in a subject, in particular HIV and HCV infections. Agents according to the invention comprise a DNA-lipid conjugate forming a G-quadruplex structure.
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: PHC-33-2015 | Award Amount: 30.12M | Year: 2016
The vision of EU-ToxRisk is to drive a paradigm shift in toxicology towards an animal-free, mechanism-based integrated approach to chemical safety assessment. The project will unite all relevant disciplines and stakeholders to establish: i) pragmatic, solid read-across procedures incorporating mechanistic and toxicokinetic knowledge; and ii) ab initio hazard and risk assessment strategies of chemicals with little background information. The project will focus on repeated dose systemic toxicity (liver, kidney, lung and nervous system) as well as developmental/reproduction toxicity. Different human tiered test systems are integrated to balance speed, cost and biological complexity. EU-ToxRisk extensively integrates the adverse outcome pathway (AOP)-based toxicity testing concept. Therefore, advanced technologies, including high throughput transcriptomics, RNA interference, and high throughput microscopy, will provide quantitative and mechanistic underpinning of AOPs and key events (KE). The project combines in silico tools and in vitro assays by computational modelling approaches to provide quantitative data on the activation of KE of AOP. This information, together with detailed toxicokinetics data, and in vitro-in vivo extrapolation algorithms forms the basis for improved hazard and risk assessment. The EU-ToxRisk work plan is structured along a broad spectrum of case studies, driven by the cosmetics, (agro)-chemical, pharma industry together with regulators. The approach involves iterative training, testing, optimization and validation phases to establish fit-for-purpose integrated approaches to testing and assessment with key EU-ToxRisk methodologies. The test systems will be combined to a flexible service package for exploitation and continued impact across industry sectors and regulatory application. The proof-of-concept for the new mechanism-based testing strategy will make EU-ToxRisk the flagship in Europe for animal-free chemical safety assessment.
Agency: European Commission | Branch: H2020 | Program: SGA-RIA | Phase: FETFLAGSHIP | Award Amount: 89.00M | Year: 2016
Understanding the human brain is one of the greatest scientific challenges of our time. Such an understanding can provide profound insights into our humanity, leading to fundamentally new computing technologies, and transforming the diagnosis and treatment of brain disorders. Modern ICT brings this prospect within reach. The HBP Flagship Initiative (HBP) thus proposes a unique strategy that uses ICT to integrate neuroscience data from around the world, to develop a unified multi-level understanding of the brain and diseases, and ultimately to emulate its computational capabilities. The goal is to catalyze a global collaborative effort. During the HBPs first Specific Grant Agreement (SGA1), the HBP Core Project will outline the basis for building and operating a tightly integrated Research Infrastructure, providing HBP researchers and the scientific Community with unique resources and capabilities. Partnering Projects will enable independent research groups to expand the capabilities of the HBP Platforms, in order to use them to address otherwise intractable problems in neuroscience, computing and medicine in the future. In addition, collaborations with other national, European and international initiatives will create synergies, maximizing returns on research investment. SGA1 covers the detailed steps that will be taken to move the HBP closer to achieving its ambitious Flagship Objectives.
Agency: European Commission | Branch: H2020 | Program: IA | Phase: DRS-01-2015 | Award Amount: 6.73M | Year: 2017
In every disaster and crisis, incident time is the enemy, and getting accurate information about the scope, extent, and impact of the disaster is critical to creating and orchestrating an effective disaster response and recovery effort. The main goal of beAWARE is to provide support in all the phases of an emergency incident. More specifically, we propose an integrated solution to support forecasting, early warnings, transmission and routing of the emergency data, aggregated analysis of multimodal data and management the coordination between the first responders and the authorities. Our intention is to rely on platforms, theories and methodologies that are already used for disaster forecasting and management and add the elements that are necessary to make them working efficiently and in harm under the same objective. The overall context for beAWARE lies in the domain of situational awareness and command and control (C2). The first phase concerns the forecast of the extreme condition and the relevant preparations. Once a disaster occurs, an initial assessment needs to be conducted as soon as possible to determine the scope, geographical distribution, and scale of the incident. Situational awareness means being able to accurately determine what has happened, what is happening now, and what will come next, all in order to plan and coordinate the most effective response possible with the resources available. This observation phase will lead to an orientation phase suggesting both an individual as well as collective cognition orientation to data that is sensed and communicated. Once orientation to the data (or the lack of it) occurs then a decision is made, ultimately resulting is the final step, which is act. The crisis management center is always striving or struggling to gain a sense of what is reality to be able to feel that he or she can make a decision that is the best possible given the circumstances.
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: REV-INEQUAL-04-2016 | Award Amount: 4.91M | Year: 2017
The overarching goal of the project is to understand the economic, social, institutional and policy factors that have shaped the impacts of free movement and public debates about it. It aims to help European policymakers develop policy responses that inspire public trust, ensure the fairness and sustainability of free movement, and maintain inclusive policies that reduce inequalities across the continent. First, the project will generate a deeper understanding of the nature and impacts of intra-EU mobility, focusing in particular on how countries institutional and policy environments shape the impacts of free movement on individuals, households, labour markets, public services and public finances. Second, it will assess how political and media narratives about intra-EU mobility are formed, focusing on the role of traditional and social media, political discourse, and influential participants in public debates. Third, it will assess the relationship between real and perceived impacts, examining the factors that drive realities and misperceptions about free movement and why these debates have unfolded in different ways across the EU. A consortium of researchers with deep understanding of policies and institutions across Europe will implement a multi-disciplinary research strategy. Cutting-edge research methods will range from content analysis based on machine-learning techniques to multi-wave panel and survey experiments to theoretical and empirical analysis of the role of institutions and norms in shaping free movement and public debates about it. The project combines qualitative and quantitative approaches, carefully integrating work packages to allow data and results to flow seamlessly between them. Policy specialists will develop concrete options for reforms. An experienced communications team will work with consortium members to develop accessible resources, ensuring wide reach to policymakers, media practitioners and influential stakeholders across Europe.
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: SC1-PM-09-2016 | Award Amount: 6.00M | Year: 2017
Liver cirrhosis is a very common chronic disease and one of the leading causes of death in European. Moreover, cirrhosis has a marked impact in patients quality of life and represents a major burden for health systems. Treatment of cirrhosis is currently based on symptomatic management of complications and has not changed substantially in the last 20 years. There is an unmet need for therapies that target the pathobiology of cirrhosis. The objective of LIVERHOPE project is to evaluate a novel therapeutic strategy for patients with cirrhosis based on a combination of rifaximin and simvastatin, targeting the main pathophysiological mechanisms of disease progression , namely the impairment in the gut-liver axis and the persistent hepatic and systemic inflammatory response. This dual therapeutic approach is supported by preclinical data showing excellent and very promising results. We will perform two randomized double-blind trials to investigate safety, tolerability and efficacy of combination of simvastatin plus rifaximin in patients with decompensated cirrhosis in 5 EU countries (285 patients will be enrolled in two trials in DE, ES, FR, IT, UK). The expected impact is to halt progression to acute-on-chronic liver failure, the main cause of death, to decrease complications of the disease, to reduce hospital readmissions, to improve cost-effectiveness of therapy. Our final aim is to improve patients quality-of-life and increase survival as patients care is the core of LIVERHOPE. Within the project we will also investigate biomarkers of response to treatment and disease progression that can be useful in clinical practice for improving the treatment of patients. We will invest our effort also in communication and dissemination activities for increasing awareness about chronic liver diseases in European countries so that preventive measures can be established to decrease the burden of cirrhosis and reduce social stigmatization of patients with chronic liver diseases.
Gabaldon T.,University Pompeu Fabra |
Koonin E.V.,U.S. National Center for Biotechnology Information
Nature Reviews Genetics | Year: 2013
Orthologues and paralogues are types of homologous genes that are related by speciation or duplication, respectively. Orthologous genes are generally assumed to retain equivalent functions in different organisms and to share other key properties. Several recent comparative genomic studies have focused on testing these expectations. Here we discuss the complexity of the evolution of gene-phenotype relationships and assess the validity of the key implications of orthology and paralogy relationships as general statistical trends and guiding principles. © 2013 Macmillan Publishers Limited. All rights reserved.